Pregnancy outcomes after first‐trimester exposure to fluoroquinolones: Findings based on an integrated database from two Japanese institutions
Congenital Anomalies · 2024
DOI: 10.1111/cga.12577 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Congenital Anomalies, 2024. Verfasst von Mikako Goto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pregnancy and Drug Information Center, The Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Ja…. Hauptthemen laut MEDLINE: Abnormalities, Drug-Induced, Anti-Bacterial Agents, Fluoroquinolones, Pregnancy Outcome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Given the paucity of safety data on fluoroquinolone antibiotics in pregnancy, a prospective observational cohort study was conducted in pregnant women who sought help and advice on drug use at two teratology information institutes in Japan. The primary endpoint of the study was the incidence of major congenital anomalies. The study population included pregnant women exposed to (i) fluoroquinolones (fluoroquinolone group), (ii) β‐lactams (infectious control group), or (iii) other agents considered to be nonteratogenic in humans (nonteratogenic control group) during the first trimester. The frequency of major congenital anomalies was compared across groups using a logistic regression model that adjusted for maternal age, smoking status, drinking status, facility consulted, and time of consultation. The fluoroquinolone group consisted of 411 women who had 383 children born alive. The infectious control and nonteratogenic control groups consisted of 1416 and 1482 women who had 1322 and 1401 children born alive, respectively. The incidence of major congenital anomalies was 1.5%, 2.0%, and 1.6% in the fluoroquinolone group, infectious control, and nonteratogenic control groups, respectively. Logistic regression showed that fluoroquinolone exposure is not a significant risk factor for major congenital anomalies. In conclusion, first‐trimester exposure to fluoroquinolone antibiotics was not associated with increased maternal or fetal risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pregnancy and Drug Information Center, The Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan.
- Department of Biostatistics, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Pharmacy, Toranomon Hospital, Minato-ku, Japan.
ORCID-Profile: Mikako Goto, Tatsuhiko Anzai, Naho Yakuwa, Kunihiko Takahashi
Zitieren
APA
Goto, M., Anzai, T., Yamane, R., Yakuwa, N., Takahashi, K., & Murashima, A. (2024). Pregnancy outcomes after first‐trimester exposure to fluoroquinolones: Findings based on an integrated database from two Japanese institutions. Congenital Anomalies. https://doi.org/10.1111/cga.12577
Vancouver
Goto M, Anzai T, Yamane R, Yakuwa N, Takahashi K, Murashima A. Pregnancy outcomes after first‐trimester exposure to fluoroquinolones: Findings based on an integrated database from two Japanese institutions. Congenital Anomalies. 2024. doi:10.1111/cga.12577
BibTeX
@article{Goto2024,
author = {Goto, Mikako and Anzai, Tatsuhiko and Yamane, Ritsuko and Yakuwa, Naho and Takahashi, Kunihiko and Murashima, Atsuko},
title = {Pregnancy outcomes after first‐trimester exposure to fluoroquinolones: Findings based on an integrated database from two Japanese institutions},
journal = {Congenital Anomalies},
year = {2024},
doi = {10.1111/cga.12577}
}
EUVIMED